Objective
: Although long‐term prostacyclin(PGI2) therapy in patients with severe pulmonary hypertension (PH)reduces pulmonary vascular resistance (PVR), there have been noreports on its therapeutic effects in patients with mild PH. Weinvestigated the chronic effect of beraprost sodium (BPS), an oralPGI2 analog, in children with mild PH.
Methods
: We studied 20 patients who weredestined for a Fontan procedure with a mean pulmonary arterial pressure(PAP) of>20 mmHg and/or PVR of>3.0 Woodunits. Both the PAP and the PVR in these cases were too high forpatients to undergo a successful Fontan procedure. Seven patientsreceived BPS (PG group) and 13 did not (control group). All patientsunderwent repeat cardiac catheterization to examine pulmonary hemodynamics.
Results
: In the PG group, the pulmonary‐to‐systemicflow ratio (Qp/Qs) did not change after BPS administration(1.1 ± 0.6 vs 1.3 ± 0.9);however, the mean PAP decreased significantly (25.3 ± 8.2 vs 19.9 ± 6.5 mmHg; P < 0.05),as did PVR (3.7 ± 1.3 vs 2.3 ± 0.9 Woodunits; P < 0.05), whereas the pulmonaryartery (PA) index increased significantly (312 ± 136 vs 375 ± 165; P < 0.05).In the control group, the mean PAP decreased significantly (24.9 ± 4.7 vs 19.8 ± 6.3 mmHg; P < 0.05)and the PA index increased significantly (295 ± 72 vs 362 ± 114; P < 0.05).No significant changes in Qp/Qs (1.5 ± 0.8 vs 1.4 ± 0.6)or PVR (2.9 ± 1.3 vs 2.5 ± 0.8 Woodunits) were observed.
Conclusion
: We conclude that long‐termBPS administration probably reduces PVR in potential candidates fora Fontan procedure with mild PH. This treatment would reduce therisks associated with the Fontan procedure and would also improveits outcome.